Cited by 15MicroRNA in disease regulationNeurogenesis and neuroplasticity mechanismsNeuroinflammation and Neurodegeneration Mechanisms

MiR-128-3p – a gray eminence of the human central nervous system

Open access
Kiel, Klaudia, Król, Sylwia Katarzyna, Bronisz, Agnieszka, Godlewski, Jakub·2024·Molecular Therapy Nucleic Acids

Abstract

MicroRNA-128-3p (miR-128-3p) is a versatile molecule with multiple functions in the physiopathology of the human central nervous system. Perturbations of miR-128-3p, which is enriched in the brain, contribute to a plethora of neurodegenerative disorders, brain injuries, and malignancies, as this miRNA is a crucial regulator of gene expression in the brain, playing an essential role in the maintenance and function of cells stemming from neuronal lineage. However, the differential expression of miR-128-3p in pathologies underscores the importance of the balance between its high and low levels. Significantly, numerous reports pointed to miR-128-3p as one of the most depleted in glioblastoma, implying it is a critical player in the disease's pathogenesis and thus may serve as a therapeutic agent for this most aggressive form of brain tumor. In this review, we summarize the current knowledge of the diverse roles of miR-128-3p. We focus on its involvement in the neurogenesis and pathophysiology of malignant and neurodegenerative diseases. We also highlight the promising potential of miR-128-3p as an antitumor agent for the future therapy of human cancers, including glioblastoma, and as the linchpin of brain development and function, potentially leading to the development of new therapies for neurological conditions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2024.102141

Cites

239 of 239 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

  • Cites a retracted work: 10.1007/s13311-018-0649-9

    Major

    The cited work was retracted on 2018-10-14 (notice 10.1007/s13311-018-0649-9), before this paper was published (2024-03). Its authors could have known.

    Cited work 10.1007/s13311-018-0649-9 · retracted 2018-10-14 · notice 10.1007/s13311-018-0649-9 · this paper published 2024-03

  • Cites a retracted work: 10.1016/j.ejphar.2018.11.004

    Major

    The cited work was retracted on 2019-01-15 (notice 10.1016/j.ejphar.2018.11.004), before this paper was published (2024-03). Its authors could have known.

    Cited work 10.1016/j.ejphar.2018.11.004 · retracted 2019-01-15 · notice 10.1016/j.ejphar.2018.11.004 · this paper published 2024-03

2 of 2

Cites

2 retracted

Flagged first, then by citations

4 of the 243 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kiel, K., Król, S. K., Bronisz, A., & Godlewski, J.
Affiliations
Mossakowski Medical Research Institute, Polish Academy of Sciences (PL)
Corresponding author
Godlewski, Jakub
Venue
Molecular Therapy Nucleic Acids
Publisher
Elsevier BV
Published
2024-03
Volume
35
Issue
1
Pages
102141
ISSN
2162-2531 (ISSN-L)
OpenAlex
W4391560391
Cited by
15
References
243
Citations by year
2026: 7 · 2025: 5 · 2024: 3
FWCI
0.62
Type
journal article
Language
en
Open access
Locations
  • Molecular Therapy — Nucleic Acids (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Agency for Academic Exchange (PPN / PPO/2019/1/00001)
  • National Science Centre Poland (2021/41/N/NZ6/02682, 2022/45/B/NZ5/04226, 2021/41/B/NZ6/02436, 2018/29/B/NZ1/01016, 2020/39/B/NZ5/02893)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
miR-128-3p, microRNA, central nervous system, neurodegenerative diseases, neurogenesis, glioblastoma, brain tumors, brain development, neuronal lineage, cancer therapy, gene expression regulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review